A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028

放射治疗 医学 肽疫苗 随机对照试验 肿瘤科 内科学 癌症研究 免疫学 抗体 表位
作者
Yan Zhang,Ye‐Fan Hu,Lingyu Ma,Yifei Wu,Dandan Chao,Xian Chen,Zhiyuan Xu,Xiaoping Su,Wei Dai,Jiandong Huang,Pingfu Fu,Feng‐Ming Kong
出处
期刊:Frontiers in Immunology [Frontiers Media]
卷期号:16: 1538032-1538032 被引量:12
标识
DOI:10.3389/fimmu.2025.1538032
摘要

Background: Neoantigen-based vaccines show promising therapeutic potential in solid tumors such as melanoma, GBM, NSCLC, and CRC. However, clinical responses remain suboptimal in stage IV patients, due to ineffective T-cell function and high tumor burdens. To overcome these limitations, our study investigates a combination strategy using neoantigen peptide vaccines and precision critical lesion radiotherapy (CLERT), which delivers immunomodulatory doses to key tumor regions synergistically enhance immune activation and inhibit progression in multifocal stage IV patients. Materials/Methods: This is an open-label, multicenter phase II randomized study. The main objective is to evaluate the anti-tumor efficacy of personalized tumor neoantigen peptide vaccines and assess how different radiation doses synergize with vaccination in treating patients with advanced malignant tumors who have progressed after systemic therapy. Patients are stratified by cancer type and randomized 1:1 to receive either placebo with conventional treatment (including high and low dose radiotherapy) or a personalized neoantigen peptide vaccine alongside conventional treatment (including high and low dose radiotherapy). A one-way crossover design is implemented, permitting patients in the placebo arm to transition to the experimental arm upon progression. Clinical outcomes including progression-free survival and objective response rate are assessed both before and after crossover. Key inclusion criteria are as follows: 1) Patients with advanced or recurrent cancers detected by pathology and imaging, who failed first-line treatments; 2) Patients with projected survival ≥3 months and an ECOG score of 0-2; and 3) Patients with at least one predicted high-quality tumor neoantigen. Conclusion: This trial introduces an innovative combination strategy of precision radiotherapy and neoantigen vaccine. A notable feature of this study is the incorporation of a randomized control and intra-group crossover design, which is rarely utilized in neoantigen trials. The study is designed to provide critical insight into radiation-immune synergy and the clinical benefit of personalized immunization. Additionally, a basket-trial framework is employed, leveraging shared neoantigens across cancer types to improve efficiency and generalizability. This approach may reduce preparation time and cost, facilitating broader implementation of neoantigen-based immunotherapies. Altogether, this trial design represents a significant step toward translational application of tumor neoantigen vaccines and provides a platform for future combinational immunotherapy strategies. Trial registration: https://clinicaltrials.gov/study/NCT06314087, identifier: NCT06314087; www.chictr.org.cn, identifier: ChiCTR2300078055. Global Collaborative Oncology Group (GCOG) identifier: GCOG0028.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.3的应助被果果采纳,获得10
刚刚
852的应助被ZX801采纳,获得10
刚刚
刚刚
小二郎的应助被拉呀采纳,获得10
1秒前
搜集达人的应助被繁星jia采纳,获得10
1秒前
1秒前
碧蓝千兰发布了新的文献求助10
2秒前
执意完成签到,获得积分10
2秒前
kyyy发布了新的文献求助10
2秒前
12发布了新的文献求助10
2秒前
卡方完成签到,获得积分10
3秒前
爆米花的应助被fuwq采纳,获得20
3秒前
脑洞疼的应助被777采纳,获得30
3秒前
4秒前
4秒前
4秒前
ZSH发布了新的文献求助10
6秒前
MAY发布了新的文献求助30
6秒前
6秒前
7秒前
7秒前
科研通AI6.4的应助被匆匆采纳,获得10
7秒前
晗玥发布了新的文献求助10
8秒前
冷板凳发布了新的文献求助10
8秒前
Jessica完成签到,获得积分10
9秒前
鞑靼发布了新的文献求助10
9秒前
今后的应助被畅快蓝血采纳,获得10
10秒前
11秒前
kyyy完成签到,获得积分10
11秒前
zj发布了新的文献求助10
12秒前
精明玲完成签到 ,获得积分10
13秒前
12完成签到 ,获得积分10
13秒前
Triton关注了科研通微信公众号
14秒前
obtu发布了新的文献求助10
14秒前
14秒前
14秒前
zhengong完成签到,获得积分20
16秒前
17秒前
Orange的应助被善良语雪采纳,获得10
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192227
求助须知:如何正确求助?哪些是违规求助? 9578845
关于积分的说明 21862272
捐赠科研通 7791732
什么是DOI,文献DOI怎么找? 3436868
关于科研通互助平台的介绍 2560579
邀请新用户注册赠送积分活动 2483654